Propecia
(Finasteride)ApprovedSmall molecule
Finasteride is used to treat male pattern baldness (hair loss) and to reduce symptoms of an enlarged prostate gland in men, such as difficulty urinating.[2] Propecia is currently approved and in use across 14 indications[4].[1]
Propecia is one of 233 small molecule programs targeting Hyperplasia. It is currently in Approved.
14
Indications
50
Total Trials
7
Active Trials
232
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
312 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Propecia
OOrganon and Co
Approved
Lupron
EEastern Cooperative Oncology Group
Phase 3
Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Leuprorelin
TakedaPhase 3
Acetylsalicylic Acid
BayerPhase 3
GM-CSF
YY-mAbs Therapeutics
Phase 3
Perflutren Lipid Microspheres
SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer7 trials
Show 4 more trials
3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT01296672·383 enrolled
Androgenetic Alopecia7 trials
Show 4 more trials
Benign Prostatic Hyperplasia4 trials
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia
Recruiting·—·Phase 2·NCT06944145·242 enrolled
Fasting Conditions3 trials
Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions
Completed·—·Phase 1·NCT01264289·26 enrolled
Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions
Completed·—·Phase 1·NCT01264302·26 enrolled
19 more indications
Retinopathy3 trials
Labor2 trials
Bioequivalence Study of Dr. Reddy's Laboratories Limited, Finasteride Tablets 1 mg Under Fasting Condition
Completed·—·Phase 1·NCT01133444·24 enrolled
Bioequivalence Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition
Completed·—·Phase 1·NCT01133457·24 enrolled
Scar2 trials
Age1 trial
H-36731: Finasteride in Management of Elevated Red Blood Cells
Withdrawn·—·Phase 3·NCT02548117
Transurethral Resection1 trial
The Effect of Pre-operative Use of Finasteride Versus Cyproterone Acetate on Blood Loss With Transurethral Resection of Prostate
Completed·—·Phase 1·NCT04848181·60 enrolled
Resistance1 trial
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
Recruiting·—·N/A·NCT04288427·120 enrolled
Monotherapy1 trial
Non-Small Cell Lung Cancer1 trial
Clinical Trial1 trial
Unspecified3 trials
Regulatory
FDA Approval Timeline[5]
Jun 19, 1992
PROSCAR
NDA NDA020180
Dec 19, 1997
PROPECIA
NDA NDA020788
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Propecia drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Finasteride. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Steroid 5-Alpha-Reductase 2 Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- OOrganon and Co